Show simple item record

dc.contributor.authorBotana, Laura 
dc.contributor.authorIbarra-Meneses, Ana Victoria 
dc.contributor.authorSanchez Herrero, Carmen 
dc.contributor.authorMatia, Belen
dc.contributor.authorSan Martin, Juan Victor
dc.contributor.authorMoreno, Javier 
dc.contributor.authorCarrillo, Eugenia 
dc.date.accessioned2022-04-22T14:26:08Z
dc.date.available2022-04-22T14:26:08Z
dc.date.issued2021-08
dc.identifier.citationPLoS Negl Trop Dis. 2021;15(8):e0009662.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14156
dc.description.abstractVisceral leishmaniasis (VL) in patients receiving immunosuppressant drugs for autoimmune disease has been on the rise. It is important-but difficult-to know when cure has been achieved in these patients since the withdrawal of immunosuppressants during antileishmania treatment is commonly required, and there is a risk of relapse when immunosuppression is restored. The prevalence of asymptomatic infection among those immunosuppressed for autoimmune disease is also uncertain. The present work describes how cytokine release assays can be used to confirm the cure of VL, and to determine the prevalence of asymptomatic infection, in such patients. After collection of blood from volunteers (n = 108), SLA-stimulation of peripheral blood mononuclear cell cultures and of whole blood was found to induce the production of different combinations of cytokines that served to confirm recovery from VL, and asymptomatic Leishmania infection. Indeed, cure was confirmed in 14 patients, all of whom showed a specific Th1 immune response against Leishmania, and the prevalence of asymptomatic infection was determined as 21.27%. Cytokine profiles could be used to manage VL in patients with autoimmune disease, and to identify and better protect those with asymptomatic infection who are at risk of developing this disease.es_ES
dc.description.sponsorshipThis study was funded by the Instituto de Salud Carlos III through two ISCIII-AES projects: PI18CIII/00028 and DTS16III10. EC was supported by a contract from RD16CIII/0003/0002 Red de Enfermedades Tropicales, Subprograma RETICS del Plan Estatal de I+D+I 2013–2016, co-funded by FEDER “Una manera de hacer Europa”funds. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.es_ES
dc.language.isoenges_ES
dc.publisherPublic Library of Science (PLOS) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleLeishmaniasis: A new method for confirming cure and detecting asymptomatic infection in patients receiving immunosuppressive treatment for autoimmune diseasees_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID34339445es_ES
dc.format.volume15es_ES
dc.format.number8es_ES
dc.format.pagee0009662es_ES
dc.identifier.doi10.1371/journal.pntd.0009662es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) es_ES
dc.contributor.funderRETICS-Investigación colaborativa en Enfermedades Tropicales (RICET-ISCIII) (España) es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1935-2735es_ES
dc.relation.publisherversionhttps://doi.org/10.1371/journal.pntd.0009662es_ES
dc.identifier.journalPLoS Neglected Tropical Diseaseses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RD16CIII/0003/0002es_ES
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia/Subprograma Estatal de Generación de Conocimiento/PI18-ISCIII Modalidad Proyectos de Investigacion en Salud Intramurales. (2018)/PI18CIII/00028es_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/DTS16III10es_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional